Hyaluronic acid in viscous malignant mesothelioma pleural effusion by Cheah, Hui Min et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
2021 
Hyaluronic acid in viscous malignant mesothelioma pleural 
effusion 
Hui Min Cheah 
Deirdre Fitzgerald 
Amber Louw 
Edith Cowan University 
Jenette Creaney 
Y. C.Gary Lee 
Edith Cowan University 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Diseases Commons 
10.1002/rcr2.694 
Cheah, H. M., Fitzgerald, D., Louw, A., Creaney, J., & Lee, Y. C. G. (2021). Hyaluronic acid in viscous malignant 
mesothelioma pleural effusion. Respirology Case Reports, 9(1), article e00694. https://doi.org/10.1002/rcr2.694 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/9319 
Hyaluronic acid in viscous malignant mesothelioma pleural
effusion
Hui Min Cheah1,2, Deirdre Fitzgerald1,2,3 , Amber Louw4,5, Jenette Creaney2,6 &
Y. C. Gary Lee1,2,3,5
1Pleural Medicine Unit, Center for Respiratory Health, University of Western Australia, Perth, WA, Australia.
2Medical School, University of Western Australia, Perth, WA, Australia.
3Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.
4PathWest Laboratory Medicine, QEII Medical Centre, Perth, WA, Australia.
5School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
6National Centre for Asbestos Related Diseases, Perth, WA, Australia.
Keywords
Hyaluronic acid, hyaluronidase, malignant pleural
effusion, mesothelioma, viscosity.
Correspondence
Y. C. Gary Lee, Pleural Medicine Unit, Center for
Respiratory Health, University of Western Australia,
Room 533, Harry Perkins Building, 6 Verdun Street,
Nedlands, Perth, WA 6009, Australia. E-mail: gary.
lee@uwa.edu.au
Received: 18 September 2020; Revised: 3 November
2020; Accepted: 15 November 2020; Associate
Editor: Jasleen Pannu.
Respirology Case Reports, 9 (1), 2021, e00694
doi: 10.1002/rcr2.694
Abstract
Malignant pleural effusion (MPE) is common with mesothelioma. We
report two cases of extraordinarily viscous MPEs associated with mesotheli-
oma. The viscosity prohibited spontaneous gravity-dependent drainage via
indwelling pleural catheters. Our ex vivo experiments found very high
hyaluronic acid (HA) content within the fluid. Treatment of the fluid with
hyaluronidase, but not with deoxyribonucleases, significantly reduced fluid
viscosity. The results provide proof that HA can contribute to high viscosity
of pleural fluid in mesothelioma. Research into strategies of counteracting
HA properties in the management of MPEs may provide further insight.
Introduction
Pleural effusions affect over 90% of patients with malignant
pleural mesothelioma. The malignant pleural effusion
(MPE) commonly appears serosanguinous or haemorrhagic,
and can be evacuated using a range of devices, such as aspi-
ration needles, chest tube, or indwelling pleural catheter
(IPC). We report two cases of extraordinarily viscous MPEs
in mesothelioma patients. Our ex vivo experiments attrib-
uted the viscosity to the high hyaluronic acid (HA) content




A 79-year-old man presented with a left-sided pleural effu-
sion which was noted as viscous on the initial therapeutic
aspiration. Cytology confirmed malignant mesothelioma.
Upon recurrence of the MPE, an IPC (Rocket, UK) was
inserted but the thick fluid prohibited spontaneous drain-
age. He was referred to our centre for further management.
The fluid was partially evacuated by connecting the IPC
via a connector to a 60-mL syringe through which manual
suction could be applied. The viscosity of the fluid prohibi-
ted usual laboratory biochemical analyses of the fluid. In
an attempt to reduce fluid viscosity to clear the remaining
fluid, two doses of 5 mg of deoxyribonuclease (DNase) was
instilled over two days via the IPC, after which ~300 and
~200 mL of fluid were drained. The underlying lung re-
expanded on chest X-ray (CXR) and talc slurry pleurodesis
was administered via the IPC.
Unfortunately, the fluid recurred over the next four
weeks, resulting in a large multiloculated effusion associ-
ated with breathlessness and fatigue (Fig. 1A), necessitating
hospitalization. Drainage via the IPC remained difficult
because of the fluid viscosity. Four doses of intrapleural
tissue plasminogen activator (tPA) 2.5 mg and DNase
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5 mg were administered twice daily with good effect. A
fluid sample was collected after the first dose (Sample 1)
for viscosity and cytological analyses (Tables 1, 2 and
Fig. 2, respectively). A total of 2.8 L of fluid was drained
with significant radiographic improvement (Fig. 1B). How-
ever, the benefit was short-lived and fluid re-accumulated
within two weeks (Fig. 1C), during which time he received
one cycle of treatment in an immunotherapy trial. A fur-
ther attempt with tPA 2.5 mg/DNase 5 mg given in outpa-
tient clinic produced only marginal benefit. With strong
manual suction via the IPC, 380 mL of viscous fluid was
aspirated and a further 350 mL was drained the next day.
Nonetheless, a massive residual effusion remained.
The patient was readmitted two weeks later for ongoing
difficulty with IPC drainage (<100 mL each attempt)
(Fig. 1D). Sample 2 was collected for viscosity analyses
(Table 1). During the hospitalization, he received
intrapleural tPA 5 mg/DNase 5 mg and suction via the
IPC with little effect (60 and 275 mL after the first two
doses). A further attempt using tPA 10 mg and DNase
10 mg yielded 200 mL and minimal radiographic improve-
ment. He was discharged and died seven months later
from his mesothelioma.
Patient 2
A 79-year-old female presenting with a right pleural effu-
sion underwent video-assisted thoracoscopic pleural biopsy
(which showed mesothelioma) and talc poudrage. The
fluid recurred after surgery necessitating a therapeutic
Figure 1. The viscous fluid of Patient 1 made drainage via indwelling pleural catheter (IPC) difficult, resulting in large loculated collections of pleural
fluid, requiring hospital admission. The chest radiograph (A) showed almost complete opacification of the left hemi-thorax which cleared with
intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) therapy (B). However, the benefit was short-lived and significant re-
accumulation of fluid was shown on his radiograph two weeks later (C). Further treatment with escalated doses of tPA/DNase failed to produce a
response (D).
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aspirate which revealed extremely thick exudative pleural
fluid. She underwent regular therapeutic aspiration in an
outside hospital for her MPE over the next four years
(during which time she received various systemic therapy)
before she was referred to our centre for IPC insertion.
The fluid was described as thick and “jelly-like” and failed
to drain via the IPC. Manual suction via the IPC (Rocket)
was required for complete evacuation of the fluid. Talc
slurry was administered after lung re-expansion but the
pleurodesis failed.
For the following 12 months, drainage was performed
(roughly once weekly) via IPC. Sample 3 showed a typi-
cal specimen. Standard IPC suction bottles were ineffec-
tive to clear the thick fluid. Hence, the patient’s carers
were taught to perform IPC drainage using manual
suction.
After one year, IPC drainage failed despite the above-
mentioned measures causing significant breathlessness
necessitating a hospital admission. A trial of
intrapleural tPA 2.5 mg/DNase 5 mg was successful and
drained 1.5 L with significant radiographic clearance.
Regular IPC drainage was re-established. Her mesothe-
lioma continued to progress and she died 10 months
later.
Fluid Viscosity and HA Analyses
Pleural fluid viscosity was determined as described by
Simpson et al. [1]. HA concentrations were determined in
the MPE supernatant using a commercially available HA
binding assay (Corgenix, USA). To test the contribution of
HA to the viscosity of the effusion, samples were incubated
at room temperature for 10 min with hyaluronidase type
V (0–100 U/mL) diluted in phosphate-buffered saline
(both Sigma-Aldrich, USA). To model the effects of
recombinant human DNase (rhDNase) treatment, the
original pleural effusion sample was incubated in the labo-
ratory with rhDNase (Pulmozyme®; Roche, USA) diluted
in normal saline (Baxter, Australia) for 4 h before viscosity
measurement.
We found that MPE from both patients had very high
pleural fluid HA concentrations. Hyaluronidase, but not
rhDNase, was effective in reducing the viscosity of the
fluid in a dose-dependent manner (Tables 1, 2, Video S1).
Discussion
We described two mesothelioma patients with HA-rich
and extremely viscous MPE, limiting fluid drainage. Our
Table 1. Pleural fluid HA concentrations and viscosity levels (mPas) of pleural fluid after incubation with
hyaluronidase (U/mL).
HA concentration in pleural fluid
Fluid viscosity (mPas) after treatment with different concentrations
of hyaluronidase (U/mL)
0 1 10 100
Patient 1
(Sample 1)
2.66×106 ng/mL 800.21 54.62 21.91 2.94
Patient 1
(Sample 2)
5.39×106 ng/mL Too viscous Too viscous 153.67 18.61
Patient 2
(Sample 3)
2.31×106 ng/mL 303.03 168.01 6.59 2.87
The two samples from Patient 1 were taken about 38 days apart.
HA, hyaluronic acid.
Table 2. Pleural fluid viscosity levels (mPas) of pleural fluid after incubation with rhDNase.
rhDNase (μg/mL)
0 2.5 5 10
Patient 1 (Sample 1) 780.56 690.93 627.61 567.38
Sample 1 was incubated with rhDNase at 2.5, 5, and 10 μg/mL at room temperature for 4 h before viscosity was measured. The range of concen-
tration selected was to approximate the concentration of enzyme in a patient with a 1.5-L pleural effusion treated with 5 mg of rhDNase.
rhDNase, recombinant human deoxyribonuclease.
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laboratory work confirmed that HA, present in high con-
centrations in these fluids, likely contributed to the high
viscosity which could be significantly reduced using
hyaluronidase.
MPE from mesothelioma contains a vast number of
important mediators. Mesothelioma has been known to
express HA for over 80 years and HA pleural fluid concen-
trations are a valuable ancillary test for diagnosis. In our
previous study including 96 mesothelioma patients, the
pleural fluid HA level has an area under the curve of 0.89
in its diagnostic value of mesothelioma, highly comparable
with mesothelin. Pleural fluid HA has also prognostic
values [2]. Our experiments provide proof to the long sus-
picion that HA is involved in generating high viscosity
in MPE.
HA is a long polymer of disaccharides up to 20,000 kDa
in size produced by hyaluronan synthases, present in
abundance in extracellular matrix. It can promote inflam-
mation and angiogenesis—processes involved in MPE for-
mation. HA is approved as intra-articular treatment for
osteoarthritis and for use in ophthalmologic conditions. It
is also a common ingredient in skin care products [3].
HA can be degraded by hyaluronidases, a family of
enzymes, and by various non-enzymatic reactions
(e.g. acidic/alkaline hydrolysis) [4]. Hyaluronidases have
been used in low doses in various conditions, mainly to
breakdown extracellular matrix and enhance drug distribu-
tion [5,6]. Whether it can be safely applied intrapleurally
and in sufficient therapeutic quantity to lyse HA in human
MPE will need to be investigated.
At present, clinically available options for viscous MPE
are limited. Use of tPA/DNase enhanced the evacuation of
thick infected pleural fluid in clinical trials. The regime
provided some short-term benefits in Patient 1, but subse-
quent administration did not prove effective. Our ex vivo
experiments did not find a major role of rhDNase in
reducing the viscosity. As tPA is known to stimulate signif-
icant production of pleural fluid in healthy and diseased
pleura, it is possible that the dilutional effect of this fluid
formation helped with initial drainages. Whether tPA itself
affects viscosity of MPE is unknown.
The composition of pleural fluid may be important to
provide an informed clinical decision to ascertain an effec-
tive therapy for pleural effusion management. In cases of
viscous fluid and high HA levels, strategies to counteract
HA production or enhance its breakdown warrant
exploration.
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Figure 2. The cytology sample from Patient 1 demonstrated material
consistent with hyaluronic acid (HA) both in intracellular and extracellu-
lar locations. The smear of the viscous pleural fluid (A) shows promi-
nent extracellular granular material within the background consistent
with HA (Diff-Quick stain, original magnification, 10×). The cell block
(B) of the same pleural fluid demonstrates malignant mesothelioma
cells with prominent intracytoplasmic vacuoles containing eosinophilic
material either with a globular appearance or an appearance similar to
that of crinkled paper, both of which suggest the presence of
hyaluronan (haematoxylin and eosin, original magnification, 40×).
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Video S1. Highly viscous pleural fluid from Patient
1 (Sample 2) in the tube labelled untreated is shown.
Treatment of the same sample with hyaluronidase
(100 U/mL for 10 min) significantly reduced the fluid
viscosity as shown in the tube labelled treated.
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